Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02712008 · ClinicalTrials.gov registry record · Phase 2

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

A Phase 2 study of Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
302
Enrollment target
20
Study locations

NCT02712008 is a Phase 2 study of Diabetic Macular Edema that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 302 participants, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02712008, a Phase 2 study of Diabetic Macular Edema, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
302 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

Conditions Studied

Diabetic Macular Edema

Interventions

  • DRUG REGN910-3
  • DRUG Intravitreal Aflibercept Injection (IAI)

Study Locations (20)

California

  • - Arcadia
  • - Beverly Hills
  • - Mountain View
  • - Oceanside
  • - Palm Desert

Florida

  • - Lakeland
  • - Tampa
  • - Winter Haven

Arizona

  • - Mesa
  • - Tucson

Georgia

  • - Augusta
  • - Decatur

Colorado

  • - Colorado Springs

Connecticut

  • - New London

Hawaii

  • - ‘Aiea

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 302 participants
Start Date 2016-03-02
Est. Completion 2017-07-10
Phase Phase 2

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02712008

The ClinicalTrials.gov registry entry for NCT02712008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which REGN910-3 is the first listed.

NCT02712008 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02712008 about?

NCT02712008 is a clinical study titled "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema". The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

What is the current status of trial NCT02712008?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2016-03-02. Estimated completion is 2017-07-10.

What conditions does trial NCT02712008 study?

This clinical trial studies the following conditions: Diabetic Macular Edema.

What interventions are being tested in trial NCT02712008?

The interventions under investigation include: REGN910-3 (DRUG), Intravitreal Aflibercept Injection (IAI) (DRUG).

Who is sponsoring clinical trial NCT02712008?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02712008 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Macular Edema

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.